Sacramento, CANCT05197270Now EnrollingIRB Ready

Macular Degeneration Clinical Trial in Sacramento, CA

Access cutting-edge macular degeneration treatment through this phase 1/2 clinical trial at a research site in Sacramento. Study-provided care at no cost to qualified participants.

Sponsored by 4D Molecular Therapeutics

Quick Self-Assessment

See if you qualify for this Sacramento location

Preparing your pre-screening questions…

Expert Care in Sacramento

Access macular degeneration specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related macular degeneration treatment provided free

Apply for This Sacramento Location

Check if you qualify for this macular degeneration clinical trial in Sacramento, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Sacramento

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Sacramento site if eligible
  4. 4Begin participation

About This Macular Degeneration Study in Sacramento

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.

Sponsor: 4D Molecular Therapeutics

Who Can Participate

Inclusion Criteria

≥50 years of age
Diagnosed with CNV secondary to AMD (confirmed by reading center)
BCVA ≥34 ETDRS letters (\~20/200) in the contralateral eye, and BCVA in the study eye:
Central subfield thickness (CST) and/or presence of subretinal or intraretinal fluid requiring continued anti-VEGF therapy in the study eye, as assessed by SD-OCT; and confirmed by a reading center):
Study eye amenable to IVT injection
Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures
Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye AND has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening: Note: Day -7 aflibercept will be administered ≥ 4 weeks from last IVT anti-VEGF
Subjects receiving 4D-150 agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period
Medical records available to document history of anti-VEGF therapy (dates, drugs, and dosage) for a minimum of 12 months prior to Screening
Provide written informed consent. Contralateral Eye Sub-study-Specific Criteria:
Received 4D-150 in study eye-1 at least 6 months prior to Contralateral Substudy Screening Visit NOTE: Subjects who received 4D-150 in study eye-1 as part of the Shedding Substudy are also eligible to participate in the Contralateral Eye Substudy only after biological samples from all matrices were at or below the limit of quantitation for vector genomes in at least 3 consecutive measurements AND at least 6 months has passed since 4D-150 administration to study eye-1.
Macular neovascularization (MNV) secondary to AMD in study eye-2 as assessed on historical images at any time by SD-OCT (required) and FA when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by the reading center)
History of at least 1 anti-VEGF injection in study eye-2 within 6 months prior to Screening (last anti-VEGF injection must be at least 28 days prior to Day 7) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time point prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)
BCVA between 25 and 83 ETDRS letters, inclusive (20/320 20/25 Snellen) in study eye-2
Study eye-2 amenable to IVT injection
BCVA ≥34 ETDRS letters (\~20/200) in the previously treated study eye-1
Ability to comply with protocol-specified procedures and visits, in the Investigator's judgment
Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to study eye-2 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period
Provide written informed consent. Shedding Substudy-specific Inclusion Criteria:
≥50 years of age
Diagnosed with MNV secondary to AMD as assessed on historical images at any time by spectral domain optical coherence tomography (SD-OCT) (required) and fluorescein angiography when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by Reading Center)
Best corrected visual acuity (BCVA) between 10 and 83 ETDRS letters, inclusive (\~20/640 and 20/25, respectively) in the study eye at Screening
BCVA ≥34 ETDRS letters (\~20/200) in the contralateral eye
Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye; minimum of 1 injection within the last 6 months (last anti-VEGF injection must be at least 28 days prior to Day 7) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)
Study eye amenable to IVT injection
Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures, in the Investigator's judgment
Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period
Provide written informed consent.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sacramento?

Yes, this clinical trial (NCT05197270) has an active research site in Sacramento, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Macular Degeneration Treatment Options in Sacramento, CA

If you're searching for macular degeneration treatment options in Sacramento, CA, this clinical trial (NCT05197270) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sacramento research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all macular degeneration clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Sacramento, CA

See all rheumatoid arthritis clinical trials recruiting in Sacramento — not just this study.

Browse Rheumatoid Arthritis Trials in Sacramento →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsMacular Degeneration TrialsWet Age-Related Macular Degeneration TrialsAll Conditions →

Ready to Join in Sacramento?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Sacramento, CA